Polyphor Pursues Promise Of Inhaled Antibiotics To Tackle Lung Infections

An IMI-backed consortium is developing inhaled formulations of the privately held Swiss company's murepavadin and Novartis's tobramycin to reduce infections suffered by bronchiectasis and cystic fibrosis patients.